Disease · MONDO_0018078
Comparisons in its trials59
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 59
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Doxorubicin + Olaratumab vs Doxorubicin + Placebo: deaths from any cause | 170 of 257 | 158 of 249 | 506 | NCT02451943 | Trial comparisons |
| Doxorubicin + Olaratumab vs Doxorubicin + Placebo: serious adverse events | 105 of 257 | 89 of 249 | 506 | NCT02451943 | Trial comparisons |
| Aldoxorubicin vs Investigator's Choice of Treatment: deaths from any cause | 148 of 213 | 131 of 207 | 420 | NCT02049905 | Trial comparisons |
| Aldoxorubicin vs Investigator's Choice of Treatment: serious adverse events | 91 of 213 | 68 of 207 | 420 | NCT02049905 | Trial comparisons |
| Pazopanib vs Placebo: serious adverse events | 99 of 240 | 29 of 123 | 363 | NCT00753688 | Trial comparisons |
| Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel vs Part 2: Placebo + Gemcitabine/Docetaxel: Part 2: Number of Participants Who Had Relationship Between MORAb-004 Exposures and Biomarker Levels | 0 of 139 | 0 of 70 | 209 | NCT01574716 | Trial comparisons |
| PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: deaths from any cause | 9 of 76 | 18 of 76 | 152 | NCT03365791 | Trial comparisons |
| PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: serious adverse events | 31 of 76 | 4 of 76 | 152 | NCT03365791 | Trial comparisons |
| Doxorubicin vs INNO-206: Number of Participants With Treatment-related Toxicities (Adverse Events) | 29 of 40 | 75 of 83 | 123 | NCT01514188 | Trial comparisons |
| Doxorubicin vs INNO-206: deaths from any cause | 26 of 40 | 40 of 83 | 123 | NCT01514188 | Trial comparisons |
| Doxorubicin vs INNO-206: serious adverse events | 8 of 40 | 33 of 83 | 123 | NCT01514188 | Trial comparisons |
Phase 2: Olaratumab + Gemcitabine + Docetaxel (Olaratumab-naive) vs Phase 2: Olaratumab + Gemcitabine + Docetaxel (Olaratumab Pre-treated): Phase 2: Number of Participants With Treatment Emergent Anti-Olaratumab Antibodies | 0 of 77 | 0 of 43 | 120 | NCT02659020 | Trial comparisons |
| 8 mg/kg TRC105 + Pazopanib vs 10 mg/kg TRC105 + Pazopanib: deaths from any cause | 0 of 3 | 9 of 106 | 109 | NCT01975519 | Trial comparisons |
| 8 mg/kg TRC105 + Pazopanib vs 10 mg/kg TRC105 + Pazopanib: serious adverse events | 0 of 3 | 9 of 106 | 109 | NCT01975519 | Trial comparisons |
| LY573636 Target Cmax 420 µg/mL vs LY573636 Target Cmax 360 µg/mL: serious adverse events | 23 of 63 | 10 of 38 | 101 | NCT00490451 | Trial comparisons |
| SHR-1210 Plus Apatinib vs ADM Plus IFO or IFO Alone: Objective Response Rate (ORR) | 11 of 50 | 5 of 47 | 97 | NCT03711279 | Trial comparisons |
| SHR-1210 Plus Apatinib vs ADM Plus IFO or IFO Alone: deaths from any cause | 2 of 50 | 2 of 47 | 97 | NCT03711279 | Trial comparisons |
| SHR-1210 Plus Apatinib vs ADM Plus IFO or IFO Alone: serious adverse events | 27 of 50 | 13 of 47 | 97 | NCT03711279 | Trial comparisons |
| Experimental vs Standard of Care: Rate of Participants With Grade 3 or Higher Toxicity | 39 of 45 | 39 of 45 | 90 | NCT01593748 | Trial comparisons |
| Experimental vs Standard of Care: deaths from any cause | 32 of 45 | 30 of 45 | 90 | NCT01593748 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018078/comparisons